ABCB1 GENE POLYMORPHISMS ARE ASSOCIATED WITH CLINICAL RESPONSE TO NABIXIMOLS IN PATIENTS WITH MULTIPLE SCLEROSIS-RELATED SPASTICITY
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system causing severe symptoms, including spasticity-related pain. Nabiximols (NBX), a drug combining Tetrahydrocannabinol and Cannabidiol, is approved for MS-associated spasticity. Despite NBX efficacy, only 60-70% of patients respond to treatment. This study explores whether genetic polymorphisms in key genes involved in NBX pharmacology influence response to drug.
Materials & Methods
This is a genetic, exploratory study in which MS patients, treated with NBX, were retrospectively enrolled. Polymorphisms in genes related to NBX metabolism ( CYP2C9 , CYP2C19 ), efflux (ATP Binding Cassette subfamily B member 1 - ABCB1 ), and cannabinoid receptors ( CNR1 , CNR2 ) were analyzed using Real-Time PCR.
Results
Among 45 enrolled patients, 29 responded to NBX and 16 did not. Of responders, 38% were homozygous for the T allele in ABCB1 1236C>T (rs1128503), and 48% for the T allele in ABCB1 3435A>T (rs1045642). None of the non-responders carried T allele. The odds ratios for response to NBX of TT homozygotes was 20.5 (95% CI:1.1-376.1, P=0.0039) for rs1128503 and 30.9 (95% CI:1.7-563.2, P=0.0006) for rs1045642.
Discussion
This study suggests a link between genetic profiles and NBX response. If validated in larger studies, these findings could pave the way for personalized therapy for MS-related spasticity.
